Long noncoding RNA plasmacytoma variant translocation gene 1 promotes epithelial‐mesenchymal transition in osteosarcoma

Abstract

Objective Long noncoding RNAs (lncRNAs) are involved in the proliferation, migration, and invasion of tumors. In the current study, our aim was to explore the role of lncRNA plasmacytoma variant translocation gene 1 (PVT1) in osteosarcoma. Methods Quantitative real‐time reverse transcription‐polymerase chain reaction was used to detect the expression of lncRNA PVT1 in osteosarcoma tissues and cells. The relationship between lncRNA PVT1 expression status and the prognosis of patients with osteosarcoma was analyzed. The effect of lncRNA PVT1 on the malignant biological behavior of osteosarcoma cells in vitro was also analyzed. Results LncRNA PVT1 was upregulated in osteosarcoma. High lncRNA PVT1 expression indicated poor prognosis in patients with osteosarcoma. In vitro knockdown of lncRNA PVT1 inhibited the proliferation, migration, and invasion ability of osteosarcoma cells. In addition, we confirmed that lncRNA PVT1 affected the epithelial‐mesenchymal transition of osteosarcoma cells. Conclusion LncRNA PVT1 is a potential therapeutic target for osteosarcoma.

Noncoding RNA PVT1 in osteosarcoma: The roles of lncRNA PVT1 and circPVT1

“…According to Xun et al, the expression of lncRNA PVT1 was increased in both OS tissues and cell lines and was closely associated with clinical features of OS, such as tumor differentiation, TNM stage, and distant metastasis. Further research revealed that knocking out the lncRNA PVT1 in OS cells could reduce vimentin and N-cadherin expression while increasing E-cadherin expression, thus preliminarily confirming that lncRNA PVT1 promotes the occurrence of OS by regulating EMT [ 53 ]. Liu et al demonstrated that circPVT1 can serve as a “molecular sponge” to adsorb miR-205-5p, thereby promoting the expression of c-FLIP and enhancing EMT in vitro to induce OS invasion and metastasis [ 54 ].…”

“…Studies have revealed a close connection between circPVT1 and lncRNA PVT1 and the pathological and clinical characteristics of OS and can be used as important biomarkers for evaluating the prognosis of OS. Kaplan‒Meier survival analysis revealed that the lncRNAs PVT1 and circPVT1 were highly expressed in OS and were negatively correlated with survival rate, indicating the potential of these molecules as prognostic biomarkers of OS [ 46 , 53 , 56 – 58 , 68 , 77 ]. Further analysis of the above studies revealed the significant and interesting phenomenon that patients with high expression of lncRNA PVT1 and circPVT1 are most likely to have stage IIB/III OS and least likely to have stage I/IIA OS [ 53 , 56 , 58 , 68 , 77 ].…”

lncRNA PVT1: a novel oncogene in multiple cancers

“…8P). Xun et al [220] demonstrated that PVT1 promotes EMT in OS cells and is highly correlated with TNM stage and distant metastases, which may be used as an independent prognostic risk marker of OS. In addition, Chen et al [221] reported that the expression of PVT1 was upregulated in OS.…”

Analysis of anti‐apoptotic PVT1 oncogene and apoptosis‐related proteins (p53, Bcl2, PD‐1, and PD‐L1) expression in thyroid carcinoma

“…nih.gov/gene/5820). Deregulated expression of PVT1 has been demonstrated to be associated with solid organ [12][13][14] and hematological malignancies, 15 and its deregulation could be related to survival and prognosis of cancer patients. [16][17][18] Pertinent to clinical practice, PVT1 might act as a prognostic biomarker for tumors and serve as a potential target for therapy.…”

“…PVT1 gene, also named as MIR1204HG, MYC Activator, LINC00079, and Onco‐LncRNA‐100, is located on chromosome 8q24.21, 100 to 500 kb 3‐prime of MYC , hosting four microRNAs gene cluster, namely MIR1204, 1205, 1206, 1207, and 1208, and can have 176 splice variant transcripts of varying length ( https://www.ncbi.nlm.nih.gov/gene/5820 ). Deregulated expression of PVT1 has been demonstrated to be associated with solid organ 12 , 13 , 14 and hematological malignancies, 15 and its deregulation could be related to survival and prognosis of cancer patients. 16 , 17 , 18 Pertinent to clinical practice, PVT1 might act as a prognostic biomarker for tumors and serve as a potential target for therapy.…”